CN103976972B - Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and preparation method thereof - Google Patents
Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and preparation method thereof Download PDFInfo
- Publication number
- CN103976972B CN103976972B CN201410230633.1A CN201410230633A CN103976972B CN 103976972 B CN103976972 B CN 103976972B CN 201410230633 A CN201410230633 A CN 201410230633A CN 103976972 B CN103976972 B CN 103976972B
- Authority
- CN
- China
- Prior art keywords
- controlled release
- coating
- layer
- pulse
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to slow/controlled release formulation art, and in particular to a kind of Zolpidemtar Trate new oral commutator pulse controlled release drug delivery system and its preparation technology.Delivery system and combinations thereof is released in the pulse includes (A) sub-micron solid dispersion medicine；(B) solubilizing systems pastille label；(C) pulse controlled release portion, the wherein controlled release portion are made up of hydrophily barrier gown layer, hydrophobic controlled release clothing layer and enteric coating layer.The present invention solves the bioavailability concerns that medicine intestinal absorption particularly mid small bowel absorbs using new micronizing and solid dispersing sub micronic solubilization technique；The pulse controlled-release administrating system is quickly dissolved in enteral and efficiently transported through biomembrane, can form pulse peak concentration, and bioavilability is improved, and the pulse extended release time is 2~3 hours, is mainly used in treating person in middle and old age's property early awakening disease.
Description
Technical field
The invention belongs to slow/controlled release formulation art, and in particular to a kind of Zolpidemtar Trate new oral commutator pulse control
Delivery system and its preparation technology are released, the present invention is a kind of timing and controlled release preparation for treating early awakening sleep-disorder, is further carried
For pulse controlled release composition and its tablet with the full aqueous film coating of multilayer.
Background technology
The incidence of disease of China's insomnia class disease in elevated trend year by year, is accelerated, spirit because work section is rapid in recent years
It is nervous and cause the number of sleep-disorder to be continuously increased, result according to investigations：China's sleep-disorder illness rate is up to 42.7%, wherein about
There are 300,000,000 the elderly to suffer from sleep-disorder, global somnifacient market total sales volume reaches 1,300,000,000 dollars.Middle-older patient often has sleep
Difficult, early awakening insomnia, the wherein incidence of disease of early awakening are in ascendant trend year by year, the early awakening patient often easy early awakening in morning 2~4 point,
Had difficulty in going to sleep after waking up, aging society early awakening morbidity healthhazard greatly, be good for by the life, work and body and mind for having a strong impact on people
Health.
Zolpidemtar Trate (trade name：" Stilnox "), belong to third generation Non-benzodiazepine hypnotic sedative agent, be clinical
Conventional short-acting medicine.Half-life period is about 2.5 hours in blood, and sleep derivation effect, effect is fast, is worked within 30 minutes after medication.Sleep
Research of sleeping finds that Zolpidemtar Trate mainly acts on the non-snap-action eye sleep phases of phase second of sleep cycle, increases or does not increase
Plus slow wave sleep, the effect that fast phase is moved to eye is slight.With obvious calm, syngignoscism and slight antianxiety, anti-epileptic and
Muscle relaxation.
Zolpidem has turned into cookle level medicine in the whole world since 2000, is the goldstandard medicine for treating sleep-disorder
Thing.The zolpidem ordinary preparation of external listing mainly had the formulations such as ordinary tablet, sublingual lozenge and oral spray in recent years, commonly
Calm dormancy tablet, capsule generally take a medicine at bedtime, rapid-onset, and effective acting time is generally 2~6 hours, early awakening patient
It need to often get up at midnight and take medicine again, seriously reduce sleep quality, very big inconvenience is brought to patient.U.S.'s NovaDel pharmacy
The zolpidem oral spray of companyShort for difficulty falling asleep insomniac；Such as Switzerland
The zolpidem sublingual lozenge of Orexo drugmakersThe azoles pyrrole of Transcept companies of the U.S.
Smooth preparation It is a kind of sublingual lozenge of quick acting, by oral cavity
Mucous membrane medicine is rapidly absorbed, for the short of difficulty falling asleep insomniac, but patient needs midnight to get up again to take medicine,
It is serious to reduce sleep quality, compliance reduction.
The zolpidem sustained release preparation of external Sanofi-Aventis company exploitation, trade name Ambien
(Zolpidem Extended-Release Tablet)。Ambien With quick acting, but pharmaceutical release time is slow
Slowly, higher level is maintained when blood concentration is long, it is larger due to discharging total medication amount, it is used for a long time and triggers next day drowsiness dizziness bright
Aobvious to improve, incidence rate of anxiety reaches 6.3%, and serious adverse reaction also has headache, gastrointestinal reaction etc..
Orally taken pulsed delivery system or Selecting time system, biological temporal rhythm feature is pressed according to the principle of chronopharmacology
Design, after oral administration, as required with the scheduled time effective therapeutic dose medicine of single or multiple pulse releases at regular time and quantity
Formulation, to reach optimum therapeuticing effect, improves the compliance of patient there is provided effective blood concentration.Suitable for asthma, sleep barrier
Hinder, the treatment of the chronic disease such as epilepsy, diabetes, arthritis and colitis (cancer).EP1194132 discloses zolpidem or its salt
Containing quick-release and slowbreak part combination pellet preparations.US2006/0159744A1 discloses the azoles containing quick-release Yu sustained release part
Pyrrole is smooth or two-phase delivery formulations of its salt, and time lag is 50~200 minutes.Chinese patent CN1334729A disclose a kind of zolpidem or
Its salt first is mutually quick-release phase, the second controlled release preparation mutually for sustained release phase.Chinese patent CN101574328A discloses a kind of azoles
Pulse releasing micropills when selecting of the smooth salt of pyrrole, micropill is made up of blank capsule core, medicine layer, organic acid layer, time lag layer, and time lag is 4 small
When, the preparation technology that medicine and organic acid are sticked to blank capsule core using medicine-feeding method, the big technology controlling and process of differences between batches is difficult.
CN102552107 discloses the compaction of pellet system that a kind of quick-release containing zolpidem or its salt is mixed containing medicinal powder and enteric-coated quick releasing capsule core
Standby technology.There is the above patent common problem from biopharmacy basic theory not consider how to study polymorphic medicine
Influence of the thing crystal formation to formulation body absorption, especially indissoluble solution and difficulty absorb the drug in whole intestinal segment, and how cross-film is sorbefacient
Problem in science；Internal blood concentration method of testing and pharmacokinetics have no patent report.
The patent of the present invention is to be directed to clinical common early awakening sleep-disorder, by from Zolpidemtar Trate pulse-controlled release preparations
The key technology of formulation design basis, pulse delivery system, preparation stability, pharmacological effect and Internal pharmacokinetics to practical application
Broken through；The dissolubility and cross-film for solving medicine with new solubilization technique science absorb, and intend to solve that pulse-controlled release preparations exist
Regularly burst releases the drug and quickly dissolves the problem in science with efficiently transporting absorption through biomembrane in enteral in intestines.Looked into according to newest
Latest report, the document and patent report of the Orally taken pulsed controlled release preparation of the type that so far there are no.
The content of the invention
Early stage of the present invention successfully carries out polymorphous characterization and evaluation, Determination of oil-water partition coefficient, dissolving before label drug prescription
The biopharmacy basic research such as property.The present invention provides a kind of Zolpidemtar Trate pulse controlled-release administrating system, especially provides one
The sub-micron solid dispersion medicine and solubilized system of high-dissolvability are planted, the preferred Zolpidemtar Trate of physical pharmaceutics method is utilized
Optimal crystal formation (A types, Type B and c-type), using new micronizing and solid dispersing sub micronic solubilization technique, is set using air-flow crushing
Standby to be crushed Zolpidemtar Trate particle, it is 0.1~10 μm or so to control average grain diameter；With nano junction crystallization and solid
Dispersion technology is combined, and the Zolpidemtar Trate of sub-micron and lactose, microcrystalline cellulose, pregelatinized starch are passed through into grinding technique shape
Into hydrogen bond and it is solubilized, to increase the hydrophily of Zolpidemtar Trate and in duodenal permeability, solve medicine intestinal absorption
The bioavilability problem that particularly mid small bowel absorbs.
The present invention provides a kind of Orally taken pulsed controlled release system of Zolpidemtar Trate, makes its label fater disintegration, at label
Organic acid such as citric acid, tartaric acid are added in side, rate of release of the medicine in intestines is improved；Added in Core formulation new and effective
Disintegrant (PVPP, Ac-Di-Sol etc.), makes pulsatile release tablets certain position in intestines to absorb water rapidly
Expand and discharge completely；The preparation technology ensure that content is accurate, and the drug release rate of the Orally taken pulsed delayed release tablet is not by label
The influence of pressure.
The present invention provides a kind of Orally taken pulsed controlled release system of Zolpidemtar Trate and preparation method thereof, specific new using environmental protection
The pulse packaging technique of the complete aqueous double-deck film coating timing explosion of type, utilizes the original for being coated dissolution and the releasing mechanism that happens suddenly is combined
Reason, with modern efficient coating equipment in sugar production line, water barrier is packed by label, controlled release is wrapped up again and enteric Double-layer pulse controlled release clothing, is prepared
Into Novel timing pulse extended release tablet, make its 3~4h timings rupture in vivo, quantitatively discharge the medicine of therapeutic dose, internal energy
Form pulsed release peak concentration；Solve and drug release is regularly happened suddenly in intestines and biomembrane height is quickly dissolved and pass through in enteral
The problem in science that effect transhipment absorbs；Solve the Orally taken pulsed controlled release tablet industrialization large-scale production problem of Zolpidemtar Trate.
The present invention provides a kind of Orally taken pulsed controlled release system of Zolpidemtar Trate and preparation method thereof, sets up in line with international standards
Pharmacokinetics technology appraisement system, medicine blood concentration is determined using the high LC-MS-MS of sensitivity in animal body, determined
The measure of impurity not interference medicament and metabolin in Zolpidemtar Trate concentration method in Beagle dog plasmas, blood plasma.This hair
It is bright provide it is a kind of treats Orally taken pulsed controlled release preparation of Zolpidemtar Trate of person in middle and old age's early awakening and combinations thereof, its is external 3~4 small
When delayed release, pulse peak concentration can be formed in vivo, oral administration biaavailability is improved, less poisonous side effect of medicine, greatly
It is big to improve patients clinical compliance.
The present invention relates to a kind of Zolpidemtar Trate pulse controlled release system and combinations thereof, it is characterised in that：The pulse is released
Preparation compositions include (A) sub-micron solid dispersion medicine；(B) solubilizing systems pastille label；(C) pulse controlled release portion；Wherein
The controlled release portion is made up of hydrophily barrier gown layer, hydrophobic controlled release clothing layer and enteric coating layer；
The sub-micron solid dispersion medicine is prepared by air-flow crushing-grinding law technology, average grain diameter control 0.1~
10 μ, according to percentage by weight Zolpidemtar Trate 5~15% containing micronizing, solid dispersible carrier contains 5~50%；
The sub-micron solid dispersion medicine is prepared by air-flow crushing-grinding law technology, average grain diameter control 0.1~
10 μm, according to percentage by weight Zolpidemtar Trate 5~15% containing micronizing, dispersible carrier containing solid 5~50%；
The solubilizing systems pastille label according to percentage by weight sub-micron solid disperse Zolpidemtar Trate be 4~
10%, organic acid is 1.0~8.0%, and filler is 20~70%, and superdisintegrantes are 2~10%, and binder is 1~8%,
Lubricant is 0.3~0.8%；
Above-mentioned solid dispersion carrier be selected from granulation lactose such as GranuLac140,200、
GranuLac230, direct tablet compressing lactose such as Tablettose70Tablettose80, Tablettose100, FlowLac90,
FlowLac100；Microcrystalline cellulose is conventional to be hadPH types andSeries of products such as Avicel PH-101,
Avicel PH-102, Avicel PH-103, Avicel PH-105, Avicel PH-301, Avicel PH-113, compressibility
The one or two such as starch, PVP K30/PVPK29/32, Macrogol 4000, Macrogol 6000；
The organic acid is selected from the one or two such as citric acid, tartaric acid, adipic acid, malic acid, glutaric acid；The filling
Agent is selected from microcrystalline cellulose PH series, granulation lacto-series, direct tablet compressing lacto-series, amylum pregelatinisatum, mannitol, shallow lake
Powder, lactose class premixing auxiliary material series of products such as CellactoseMicrocelac Starch premixing auxiliary material
StarCap1500, mannitol premixing auxiliary materialThe one or two such as DC；The superdisintegrantes are selected from crosslinking carboxylic first
Base sodium cellulosate (CC-Na), PVPP (cross-linked pvp), sodium carboxymethyl starch (CMS-Na), low-substituted hydroxypropyl cellulose
Deng；The binder be selected from hydroxypropyl methylcellulose (HPMC), PVP PVP), sodium carboxymethylcellulose (CMC-Na), hydroxypropyl
Cellulose (HPC), the purified water of methylcellulose (MC) or alcohol solution；The lubricant is selected from magnesium stearate, talcum powder, micro-
The one or two such as powder silica gel, polyethylene glycol；
The barrier gown layer material of the pulse controlled release portion is that water-soluble material is selected from HPMC, hydroxypropyl fibre
Tie up element, PVP, the entitled Opadry in commercial goods；Also selected from methacrylic acid-Dimethylaminoethyl Methacrylate-methyl
Methyl acrylate copolymer, the serial auxiliary material of the entitled Utech in commercial goods, concrete model is Utech E100, Utech E PO,
It is preferred that HPMC or Opadry, coating weight gain are calculated as 1%~6% by label；
The hydrophobic controlled release clothing layer coating material is selected from insoluble polymer, including the conventional polymer of pharmaceutical arts
Such as Aquacoat, trade nameOrAcrylate, methyl methacrylate and methyl
The copolymer systems that acrylic acid trimethyl ammonium chloride base ethyl ester is constituted, commercial goods are entitledConcrete model includes Utech
RL30D, Eudragit RS 30D, Utech NE30D etc., coating weight gain is calculated as 3%~15% by label；
The enteric coating layer coating material is selected from methacrylic acid copolymer, the copolymer of methacrylate, commercially available business
The name of an article is Utech, and concrete model includes Eudragit L100, Eudragit S100, EudragitL100-55, Eudragit
L30D-55, Eudragit FS30D etc., preferably Utech L30D-55, Eudragit L100 aqueous dispersions；Also it can select hydroxypropyl
Methylcellulose phthalate ester (HPMCP), acetic acid hydroxypropyl methylcellulose succinate (HPMCAS), CAP (CAP),
Polyvinyl acetate phthallate (PVAP) aqueous dispersion or acetone soln；Coating weight gain is calculated as 4%~25% by label；
Water soluble pore formers such as low viscosity hydroxypropyl methylcellulose, hydroxypropyl cellulose, poly- dimension can be added in controlled release clothing layer
Ketone, methylcellulose etc., adjust rate of release, and pore-foaming agent is calculated as 1%~8% by label；
The present invention relates to the preparation method of the Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and combinations thereof, including with
Lower step：
A. the preparation of sub-micron solid dispersion medicine：Weigh Zolpidemtar Trate raw material appropriate, put in airslide disintegrating mill, if
Powder discharge pressure is put for 3~8bar, 1~5bar of grinding pressure, 0.3~1.0g/min of powder feed rate, grinding time is
10~40min, micronizing crushing is carried out by particle, and continuous to crush twice, it is 0.1~10 μm or so to control average grain diameter, is produced
Micronized medicine；
Micronized medicine is weighed appropriate, with solid hydrophilic dispersible carrier such as lactose, microcrystalline cellulose, amylum pregelatinisatum etc.
Cube blender (KB15S, ERWEKA, Germany) is put, 150~250rpm of rotating speed is set, 5~30min is mixed；Solid is taken to disperse
Thing mixing medicine is put in small grinder, adds zirconium oxide balls, grinds 2~4h, i.e. sub-micron solid dispersion medicine；
B. the preparation of solubilizing systems pastille label：Weigh above-mentioned sub-micron solid dispersion medicine, organic acid, filler, height
Effect disintegrant puts small-sized V-Mixer and mixes 5~25min, puts High Speed Stirring Machine, plus binder is pelletized in right amount, in 40~
50 DEG C of oven drying 30min~2h, whole grain, tabletting produces solubilizing systems core containing Zolpidem Tartrate；
C. the preparation process of pulse controlled release portion comprises the following steps：
(1) barrier gown layer：Weigh solubilizing systems core containing Zolpidem Tartrate to put in high-efficiency coating pot, preheating temperature control
In 25~35 DEG C, 35~50 DEG C of EAT, 25~35 DEG C of temperature of outgoing air, 25~35 DEG C of piece bed tempertaure, coating pan rotating speed 8-
15rpm, 2~10g/min of spray rate, start the continuous water solubility coating solution that sprays into and coat label, to be sprayed to finish, and blow in height
Imitate in coating pan and dry 20~35 minutes, produce barrier gown layer coating tablet.
(2) controlled release layer coatings：Above-mentioned bag separation layer label is put in high-efficiency coating pot, preheating temperature is controlled 30~35
DEG C, 35~45 DEG C of EAT, 25~35 DEG C of temperature of outgoing air, 25~38 DEG C of piece bed tempertaure, coating pan rotating speed 12-20rpm, spraying
5~10g/min of speed, starts the continuous hydrophobic coating agent that sprays into and coats separation layer, treat that whitewashing is finished, send hot blast in efficient packet
Dried 30~40 minutes in clothing pot, produce controlled release layer coating tablet.
(3) enteric layer coatings：Controlled release layer coating tablet is put in high-efficiency coating pot, 30~35 DEG C, EAT are preheated to
35~45 DEG C, 25~35 DEG C of temperature of outgoing air, 25~40 DEG C of piece bed tempertaure, coating pan rotating speed 10-25rpm, 8~20g/ of spray rate
Min, starts the continuous enteric-coating material that sprays into and coats controlled release layer, treat that whitewashing is finished, send hot blast to dry 30 in high-efficiency coating pot
~40 minutes, put 40 DEG C of baking oven for drying solidification 12 hours, produce pulse controlled release coat piece.
The present invention provides a kind of Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and combinations thereof, it is characterised in that：
Also need to add plasticizer, the increasing in the barrier gown layer of the pulse controlled release portion, the coating solution of controlled release layer and enteric coat layer
Mould agent be selected from triethyl citrate, phthalic acid diformazan/second/the third/butyl ester, dibutyl sebacate, castor oil, polyethylene glycol,
The one or two such as propane diols, Tween-80, barrier gown strata ethylene glycol, propane diols；Controlled release layer and enteric layer optimization citric acid three
Ethyl ester, dibutyl sebacate, plasticizer consumption 2-35%.
Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate of the present invention and combinations thereof, it is characterised in that：The arteries and veins
Also need to add in the coating solution of barrier gown layer, controlled release layer and the enteric coat layer of rushing controlled release portion and contain antiplastering aid, defoamer, screening
Photo etching and colouring agent；Antiplastering aid is selected from talcum powder, magnesium stearate, glycerin monostearate, calcium stearate, stearic acid, stearoyl
Alcohol fumaric acid sodium etc.；Defoamer selects dimethicone, the preferred titanium dioxide of opacifier；Colouring agent is selected from each natural and synthetic drug
Use pigment.
The present invention relates to Orally taken pulsed controlled release system of a kind of Zolpidemtar Trate and preparation method thereof, it is characterised in that：Should
The preparation that pulse controlled-release administrating system is provided is mainly used in treating person in middle and old age's property early awakening disease, and preparation characteristic is patient just before going to bed
Medication, it is oral after in stomach and duodenum upper end without insoluble drug release, delayed during by 3~4h, the regularly burst release in enteron aisle
Medicine, quickly dissolves in enteral and is transported through biomembrane efficient absorption, can form pulsed release peak concentration, suffer from early awakening
Person obtains high dose sedative-hypnotic effect and is allowed to continue to sleep, patient gets up medication without midnight when that will regain consciousness, also without delaying
The delayed drowsiness side effect of release tablet formulations, to overcome external sustained release preparation AmbienSecond day drowsiness, dizzy, spiritual not good
Etc. the residual effect brought when taking sleeping medicine.
The present invention provides a kind of Orally taken pulsed controlled release system of Zolpidemtar Trate and preparation method thereof, and the new preparation technology is adopted
With full aqueous film coating's material, with environmental-protecting performance, and the high-efficiency coating of separation layer, controlled release clothing layer and enteric pulse clothing is coated
Equipment skill thin film coating material, with environmental-protecting performance, and coats the high-efficiency coating of separation layer, controlled release clothing layer and enteric pulse clothing
Equipment and technology is advanced, favorable reproducibility, and stable preparation process is suitable for industrialized production；Present system solves pulse control
Multiple key technologies of release formulation, determine small dose drug Zolpidemtar Trate content using international advanced quality standard, release
Degree of putting and relevant material, its drug release rate are not influenceed by label pressure；The Orally taken pulsed controlled release of Zolpidemtar Trate is improved comprehensively
Security, validity, quality controllability and the compliance of novel formulation clinical practice.
Brief description of the drawings
Fig. 1 is Zolpidemtar Trate of the present invention, micronizing medicinal powder and Zolpidemtar Trate solid dispersion scanning electron microscope (SEM) photograph
A. Zolpidemtar Trate raw material；B. Zolpidemtar Trate raw material is micronized；C. Zolpidemtar Trate is micronized and breast
Sugared solid dispersion；
D. Zolpidemtar Trate is micronized and microcrystalline cellulose solid dispersion
Fig. 2 is Zolpidemtar Trate pulsatile release tablets R of the present invention1In-vitro release curves (n=6)
Fig. 3 is Zolpidemtar Trate pulsatile release tablets R of the present invention2~R4In-vitro release curves (n=6)
Embodiment
Raw material is originated and specification with auxiliary material：Zolpidemtar Trate (medicinal, Jiangsu Hao Sen pharmaceutical Co. Ltds), pharmaceutic adjuvant
It is routine；Lactose (200, MEGGLE)；Microcrystalline cellulose (PH-101, FMC)；PVP K30 (30, BASF AG)；HPMC (5mPas, Shanghai Ka Lekang technology coatings Co., Ltd)；Aquacoat ECD are (beautiful
FMC Corp. of state).
Embodiment 1
R1Core formulation：
Preparation technology：
(1) preparation of sub-micron solid dispersion medicine
A. the preparation of micronized medicine：55g Zolpidemtar Trate raw materials are weighed, are put in airslide disintegrating mill, set powder defeated
Pressurization pressure is 4bar, grinding pressure 2bar, and powder feed rate 0.5g/min, grinding time is 30min, and particle is carried out into micro mist
Change and crush, it is continuous to crush twice, micronized medicine (0.5-3 μm of average grain diameter) is produced, yield is 91%；
B. the preparation of sub-micron solid dispersion medicine：Weigh 50g micronized medicines, with 290g solid dispersible carriers lactose (200) cube blender is put, rotating speed is 180rpm, mixes 10min；Solid dispersion mixing medicine is taken to put microspheric form
In grinding machine, zirconium oxide balls are added, 2h is ground, produces sub-micron solid dispersion medicine.Its scanning electron microscope (SEM) photograph is shown in Fig. 1.
(2) preparation of solubilizing systems pastille label：Weigh 339g sub-micron solid dispersion medicines to put in mixer, then weigh
200g microcrystalline celluloses are added in mixer with 11g tartaric acid and mixed, and are adding 36g sodium carboxymethyl starch mixing 10min, use
2% PVP K30 alcohol solution prepares particle, puts in baking oven 50 DEG C of dryings 2 hours, 18 mesh sieve whole grains, plus 2.5g magnesium stearates
5min is mixed, compressed cores are rushed with 6mm scrobiculas.
R1It is coated prescription (5000 slice prescriptions, 0.6Kg tablets)：
Coating process：
Solubilizing systems core containing Zolpidem Tartrate is weighed, is put in high-efficiency coating pot, preheating temperature is 25 DEG C, and EAT is
45 DEG C, temperature of outgoing air is 28 DEG C, and 25 DEG C of piece bed tempertaure, coating pan rotating speed is 12rpm, and spray rate is 4g/min, is started continuous
HPMC coating solutions cladding label is sprayed into, to be sprayed to finish, air-supply is dried 25 minutes in high-efficiency coating pot, produces R1Barrier gown
Layer coating tablet (coating weight gain is 2%).
The preparation of controlled release coat liquid：Weigh 100g Eudragit L100 plus 65% purified water, mechanical agitation 5min, slowly
Add 56g1moL/LNH3Solution, stirs 40min, adds 50g triethyl citrates, 50g talcum powder, plus 15% purified water,
10min is homogenized with high shear homogenization machine, Eudragit L100 aqueous dispersions are produced；Separately weigh 60g Aquacoat ECD (30%
Aquacoat), 3.5g dibutyl sebacates, 805g purified waters, high shear homogenization machine homogenizes 10min, by enteric
Aqueous dispersion is well mixed with above-mentioned solution, produces controlled release layer coating solution.
Above-mentioned cladding spacer layer coating piece is taken to put in right amount in high-efficiency coating pot, preheating temperature is 35 DEG C, and EAT is 40
DEG C, 25 DEG C of temperature of outgoing air, piece bed tempertaure is 30 DEG C, and coating pan rotating speed 15rpm, spray rate 6g/min continuously spray into controlled release layer
Coating solution cladding isolation synusia, treats that whitewashing is finished, send hot blast, dry 35 minutes, then puts 40 DEG C of baking oven for drying solidification 12 hours, i.e.,
Obtain R1Pulse controlled release coat piece (coating weight gain is 10%).
Embodiment 2
R2Core formulation：
Preparation technology：
(1) preparation of sub-micron solid dispersion medicine
A. the preparation of micronized medicine：53g Zolpidemtar Trate raw materials are weighed, are put in airslide disintegrating mill, set powder defeated
Pressurization pressure is 5bar, grinding pressure 3bar, and powder feed rate 0.6g/min, grinding time is 35min, and particle is carried out into micro mist
Change and crush, it is continuous to crush twice, micronized medicine (0.2-5 μm of average grain diameter) is produced, yield is 94%；
B. the preparation of sub-micron solid dispersion medicine：50g micronized medicines are weighed, with 250g solid dispersible carrier compressibility
Starch puts cube blender, and rotating speed is 150rpm, mixes 15min；Solid dispersion mixing medicine is taken to put in small grinder, plus
Enter zirconium oxide balls, grind 3h, produce sub-micron solid dispersion medicine.
(2) preparation of solubilizing systems pastille label：Weigh 339g sub-micron solid dispersion medicines to put in mixer, then weigh
175g microcrystalline celluloses are added in mixer with 12.5g succinic acid and mixed, and are mixed adding 50g low-substituted hydroxypropyl celluloses
15min, particle is prepared with 2%HPMC alcohol solutions, puts in baking oven 50 DEG C of dryings 2 hours, 18 mesh sieve whole grains, plus 2.5g stearic acid
Magnesium mixing 8min, compressed cores are rushed with 6mm scrobiculas.
It is coated prescription (5000 slice prescriptions, 0.55Kg tablets)：
Art for coating：
Solubilizing systems core containing Zolpidem Tartrate is weighed, is put in high-efficiency coating pot, preheating temperature is 25 DEG C, and EAT is
30 DEG C, temperature of outgoing air is 25 DEG C, and 30 DEG C of piece bed tempertaure, coating pan rotating speed is 12rpm, and spray rate is 5g/min, is started continuous
Eudragit EPO coating solutions cladding label is sprayed into, to be sprayed to finish, air-supply is dried 25 minutes, produces R2Barrier gown layer coating tablet
(coating weight gain is 3%).
Controlled release layer coating process：Coating solution is prepared：Glycerin monostearate, triethyl citrate are weighed to 50% hot water
In, Eudragit RL30D and Eudragit RS30D aqueous dispersion mixed liquors are slowly added into, mixer stirring 40min crosses 60
Mesh sieve, produces controlled release layer coating solution.Above-mentioned cladding isolation synusia is put in high-efficiency coating pot, preheating temperature is 32 DEG C, enters wind-warm syndrome
Spend for 50 DEG C, 35 DEG C of temperature of outgoing air, piece bed tempertaure is 30 DEG C, coating pan rotating speed 15rpm, spray rate 6g/min are continuous to spray into
Controlled release layer coating solution cladding isolation synusia, treats that whitewashing is finished, send hot blast, dried 40 minutes in high-efficiency coating pot, then put 40 DEG C
Baking oven for drying solidification 12 hours, produces R2Controlled release layer coating tablet (coating weight gain is 10%).
Enteric layer coating process：Eudragit L100 are added in purified water, 10min is stirred, 1mol/L hydrogen-oxygens are added dropwise
Change sodium solution, stir 30min, separately weigh triethyl citrate, talcum powder is homogenized into purified water with high shear homogenization machine
10min, above-mentioned two phase liquid is mixed, and is stirred 30min, is produced enteric coating liquid.Controlled release layer coating tablet is put into high-efficiency coating pot
It is interior, 35 DEG C are preheated to, it is 55 DEG C to set EAT, temperature of outgoing air is 35 DEG C, 30 DEG C of piece bed tempertaure, coating pan rotating speed 15rpm,
Spray rate 8g/min, starts the continuous enteric-coating material that sprays into and coats controlled release layer, treat that whitewashing is finished, send hot blast, in efficient packet
Dried 35 minutes in clothing pot, put 40 DEG C of baking oven for drying solidification 12 hours, produce pulse controlled release coat piece (coating weight gain is 8%).
Embodiment 3
R3Core formulation：
Preparation technology：
(1) preparation of sub-micron solid dispersion medicine
The preparation of micronized medicine：54g Zolpidemtar Trate raw materials are weighed, are put in airslide disintegrating mill, set powder to convey
Pressure is 6bar, grinding pressure 3bar, and powder feed rate 0.3g/min, grinding time is 35min, and particle is micronized
Crush, it is continuous to crush twice, micronized medicine (0.5-8 μm of average grain diameter) is produced, yield is 92.5%；
The preparation of sub-micron solid dispersion medicine：Micronized medicine is weighed appropriate, with solid dispersible carrier lactose
(Tablettose80) cube blender is put, rotating speed is 150rpm, mixes 20min；Solid dispersion mixing medicine is taken to put small-sized
In ball mill, zirconium oxide balls are added, 4h is ground, produces sub-micron solid dispersion medicine.
(2) preparation of solubilizing systems pastille label：Weigh 380g sub-micron solid dispersion medicines to put in mixer, then weigh
162g amylum pregelatinisatums, 38g Ac-Di-Sols are added to mixer-granulator, mix 10min, fine with 2% hydroxypropyl first
Tie up plain 0 alcohol solution and prepare particle, put in baking oven 50 DEG C of dryings 2 hours, 18 mesh sieve whole grains, plus the mixing of 2.0g superfine silica gel powders
8min, compressed cores are rushed with 6mm scrobiculas.
It is coated prescription (5000 slice prescriptions, 0.6Kg tablets)：
Art for coating：
Solubilizing systems core containing Zolpidem Tartrate is weighed, is put in high-efficiency coating pot, preheating temperature is 32 DEG C, and EAT is
45 DEG C, temperature of outgoing air is 35 DEG C, and 35 DEG C of piece bed tempertaure, coating pan rotating speed is 15rpm, and spray rate is 6g/min, is started continuous
HPMC coating solutions cladding label is sprayed into, to be sprayed to finish, air-supply is dried 25 minutes, produces R3Barrier gown layer coating tablet (is coated and increased
2.5%) weight is.
Above-mentioned cladding spacer layer coating piece is taken to put in high-efficiency coating pot, preheating temperature is 35 DEG C, EAT is 46 DEG C, row
35 DEG C of air temperature, piece bed tempertaure is 36 DEG C, and coating pan rotating speed 18rpm, spray rate 8g/min are continuous to spray into controlled release layer coating solution
Cladding isolation synusia, treats that whitewashing is finished, send hot blast, dry 35 minutes, then puts 40 DEG C of baking oven for drying solidification 12 hours, produces R3Arteries and veins
Rush controlled release coat piece (coating weight gain is 15%).
Embodiment 4
R4Core formulation：
Preparation technology：
(1) preparation of sub-micron solid dispersion medicine
The preparation of micronized medicine：55g Zolpidemtar Trate raw materials are weighed, are put in airslide disintegrating mill, set powder to convey
Pressure is 6bar, grinding pressure 3bar, and powder feed rate 0.6g/min, grinding time is 35min, and particle is micronized
Crush, it is continuous to crush twice, micronized medicine (0.1-5 μm of average grain diameter) is produced, yield is 91%；
The preparation of sub-micron solid dispersion medicine：Micronized medicine is weighed appropriate, with solid dispersible carrier Avicel PH-
103 put cube blender, and rotating speed is 200rpm, mix 15min；Solid dispersion mixing medicine is taken to put in small grinder, plus
Enter zirconium oxide balls, grind 2h, produce sub-micron solid dispersion medicine.
(2) preparation of solubilizing systems pastille label
Weigh 318g sub-micron solid dispersion medicines to put in mixer, then weigh 227g pregelatinized starch, the poly- dimension of 30g crosslinkings
Ketone is added to mixer-granulator, mixes 15min, particle is prepared with 2% PVPK29/32 alcohol solution, puts in baking oven 45 DEG C and does
Dry 2 hours, 18 mesh sieve whole grains, plus 2.6g magnesium stearate mixing 5min, compressed cores are rushed with 6mm scrobiculas.
It is coated prescription (5000 slice prescriptions, 0.6Kg tablets)：
Art for coating：
Solubilizing systems core containing Zolpidem Tartrate is weighed, is put in high-efficiency coating pot, preheating temperature is 30 DEG C, and EAT is
46 DEG C, temperature of outgoing air is 35 DEG C, and 32 DEG C of piece bed tempertaure, coating pan rotating speed is 12rpm, and spray rate is 6g/min, is started continuous
HPMC coating solutions cladding label is sprayed into, to be sprayed to finish, air-supply is dried 25 minutes, produces R4Barrier gown layer coating tablet (is coated and increased
3%) weight is.
Controlled release layer coating process：By above-mentioned R4Cladding isolation synusia is put in high-efficiency coating pot, and preheating temperature is 30 DEG C, air intake
Temperature is 45 DEG C, 35 DEG C of temperature of outgoing air, and piece bed tempertaure is 30 DEG C, coating pan rotating speed 10rpm, spray rate 7g/min, continuous spray
Enter controlled release layer coating solution cladding isolation synusia, treat that whitewashing is finished, send hot blast, dry 35 minutes, produce R4Controlled release layer coating tablet (bag
6%) clothing weightening is.
Enteric layer coating process：By R4Controlled release layer coating tablet is put in high-efficiency coating pot, is preheated to 30 DEG C, sets EAT
For 55 DEG C, temperature of outgoing air is 32 DEG C, 30 DEG C of piece bed tempertaure, coating pan rotating speed 12rpm, spray rate 6g/min, starts continuous spray
Enter enteric-coating material cladding controlled release layer, treat that whitewashing is finished, send hot blast, dried 35 minutes in high-efficiency coating pot, put 40 DEG C of bakings
Case dry solidification 12 hours, produces pulse controlled release coat piece (coating weight gain is 7%).
Embodiment 5
Vitro release is studied：Take place R1~R4Pulsatile release tablets, 6 every batch, using two annex of Chinese Pharmacopoeia 2010 edition
First method basket method carries out vitro release experiment, and rotating speed is 100rpm, and 37 DEG C+0.5 DEG C of temperature, dissolution medium volume is 900mL.
2h is determined in the hydrochloric acid solution of pH1.2~1.4, is transferred in pH6.8 phosphate buffers and determines 8h, sampling time point is 2h,
2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h and 8h sample 5mL, while filling into medium 5mL.
Chromatographic condition：Chromatographic column enlightening horse C18 posts (150 × 4.6mm, 5 μm)；Mobile phase is with acetonitrile: methanol: 0.05mol/L
Phosphoric acid solution (being 5.5 with triethylamine regulation pH)=23: 28: 49 is mobile phase, and flow velocity is：1.0mL/min；Sample size：20μL
Detection wavelength：254nm column temperatures：30℃.Determined using HPLC sample introductions, calculate accumulative release percentage, its result is shown in Fig. 2 and Fig. 3.
Embodiment 6
The research of internal blood concentration and pharmacokinetics：
Blood concentration dosage regimen：Beagle dogs 4, are divided into 2 groups, male and female half and half, A groups give commercially available " Stilnox " (ginseng
Than preparation), B groups give Zolpidemtar Trate pulsatile release tablets (R4, by test preparation), using cross matching, fasting before experiment
12h, morning is administered on an empty stomach, provides food after administration after 3h, whole experiment process can't help water.
Sample collection：Beagle dogs take blank blood 3mL on an empty stomach in 15min before administration, take the blood time (A groups)：0h and administration
0.25,0.5,0.75,1,2,3,4,6,8,10,12 and 24h afterwards；B groups：0h and administration after 1,2,2.5,3,3.5,4,4.5,5,6,
8th, 10,12 and 24h dog forelimb femoral vein bloods 1.5mL.Blood sample is stored in test tube of hepari centrifuge tube, 8000rpm centrifugation 5min, point
From blood plasma, blood plasma is stored in -29 DEG C of refrigerators.The free blood plasma concentration of zolpidem is determined using LC/MS/MS.
Chromatographic condition：Chromatographic column Shimadzu ODS C18Post (150 × 2.1mmID, i.d., 3.5 μm)；Mobile phase：Aqueous phase A：Have
Machine phase B (acetonitrile), gradient elution method；Flow velocity：0.2mL·min-1；Column oven：40℃.
Plasma sample determines blood plasma mesarcs using LC/MS/MS methods in vivo through ethyl acetate extraction process, internal standard method
Drug concentration, draws the analysis of 5 μ L sample introductions.Use DAS2.0 pharmacokinetics software to carry out pharmacokinetic model and be fitted together to (weight is C), it is comprehensive
Each index determines that Beagle dogs meet one compartment model after being administered orally, and Beagle dogs mouthful are calculated using non-compartment model parametric technique
Clothes give statistical moment parameter, C after pulsatile release tablets and ordinary tabletmaxAnd TmaxFor measured value, AUC0-24And AUC0-∞By actual measurement blood medicine
Concentration estimates that pharmacokinetic parameters are shown in Table 1 through trapezoidal integration.
Table 1Beagle dogs orally give the pharmacokinetic parameters (n=4) of Zolpidemtar Trate conventional tablet and pulsatile release tablets
After the oral Zolpidemtar Trate pulsatile release tablets of Beagle dogs and conventional tablet (Stilnox), pulsatile release tablets reach
Peak time and Cmax are respectively 1.88 ± 0.47h and 102.7 ± 54.4ng/mL, MRT0-∞For 3.73 ± 0.23h；Ordinary tablet reaches
Peak time and Cmax are respectively 0.38 ± 0.25h and 148.1 ± 66.9ng/mL, MRT0-∞For 1.39 ± 0.21h, it is averaged in vivo
Increased retention 2.0~3.0 hours.Body absorption speed extends and bioavilability increases, and predicts the pulse controlled release
Preparation prescription is reasonable in design.Due to the possible pH about 4.5 of Beagle dogs intestines and stomach, therefore body absorption speed may relatively fast, root
The target of desired design has been reached according to chronopharmacology and acology principle this preparation.
Claims (4)
1. a kind of Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate, it is characterised in that：The pulse controlled-release administrating system includes
(A) solubilizing systems pastille core segment；(B) pulse controlled release portion, wherein the pulse controlled release portion by hydrophily barrier gown layer, dredge
Aqueous controlled release clothing layer and enteric coating layer composition；
The solubilizing systems pastille label, the by weight percentage Zolpidemtar Trate 5~15% containing micronizing, solid dispersion
Carrier 5~50%, organic acid 1.0~8.0%, filler 20~70%, superdisintegrantes are 2~10%, binder 1~8%,
Lubricant 0.3~0.8%；
Above-mentioned solid dispersion carrier is selected from granulation lactose, direct tablet compressing lactose, microcrystalline cellulosePH types, it can press
One or both of property starch；
The organic acid is selected from one or both of citric acid, tartaric acid, adipic acid, malic acid, glutaric acid；The filler
Selected from microcrystalline cellulose Avicel PH-101, microcrystalline cellulose Avicel PH-102, microcrystalline cellulose Avicel PH-103,
One or both of granulation lactose, direct tablet compressing lactose Tablettose 80, amylum pregelatinisatum, mannitol, starch；
The superdisintegrantes are selected from Ac-Di-Sol, PVPP, sodium carboxymethyl starch, low substituted hydroxy-propyl fiber
Element；The binder is selected from hydroxypropyl methylcellulose, PVP, sodium carboxymethylcellulose, hydroxypropyl cellulose, methylcellulose
Purified water or alcohol solution；The one kind or two of the lubricant in magnesium stearate, talcum powder, superfine silica gel powder, polyethylene glycol
Kind；
The barrier gown layer material of the pulse controlled release portion be selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose, PVP,
EudragitE100, Eudragit E PO, coating weight gain are calculated as 1%~6% by solubilizing systems pastille label；
The coating material of controlled release clothing layer is selected from water-insoluble Aquacoat, Eudragit RL 30D,
Eudragit RS30D、Eudragit NE30D；Coating weight gain is calculated as 3%~15% by solubilizing systems pastille label；Wherein, institute
The water-insoluble Aquacoat stated is selected from trade nameOr
The enteric coating layer coating material be selected from Eudragit L100, Eudragit S100, Eudragit L100-55,
Eudragit L30D-55, Eudragit FS30D, coating weight gain are calculated as 4%~20% by solubilizing systems pastille label；
Water soluble pore formers regulation rate of release is added in controlled release clothing layer, pore-foaming agent is low-viscosity hydroxypropyl methylcellulose, hydroxypropyl
Cellulose, PVP, methylcellulose, the consumption of pore-foaming agent are calculated as 1%~8% by controlled release coating layer weightening；
The preparation method of the Orally taken pulsed controlled-release administrating system of described Zolpidemtar Trate, step is as follows：
(1) preparation of solubilizing systems pastille label：Weigh Zolpidemtar Trate raw material appropriate, put in airslide disintegrating mill, powder is set
Last discharge pressure is 3~8bar, grinding pressure 1~5 bar, 0.3~1.0g/min of powder feed rate, grinding time is 10~
40min, micronizing crushing is carried out by particle, and continuous to crush twice, it is 0.1~10 μm to control average grain diameter, produces micro mist chemical drug
Thing；Weigh micronized medicine appropriate, add solid dispersion carrier and put cube blender, 150~250rpm of rotating speed is set, mix
Close 5~30min；Take said mixture to put in small grinder, add zirconium oxide balls, grind 2~6h, produce sub-micron solid
Scattered medicine；Weigh above-mentioned sub-micron solid dispersion medicine, organic acid, filler, superdisintegrantes put small-sized V-Mixer mix
5~25min is closed, mixture is then put into High Speed Stirring Machine, plus binder is pelletized in right amount, in 40~50 DEG C of oven dryings
30min~2h, plus lubricant whole grain, tabletting, produce solubilizing systems pastille label；
(2) preparation of pulse-controlled release preparations：Weigh solubilizing systems pastille label to put in high-efficiency coating pot, preheating temperature is controlled 25
~35 DEG C, 35~50 DEG C of EAT, 25~35 DEG C of temperature of outgoing air, 25~35 DEG C of piece bed tempertaure, coating pan rotating speed 8-15rpm,
2~10g/min of spray rate, starts the continuous water solubility coating solution that sprays into and coats label, treat that whitewashing is finished, blow in high-efficiency coating
Dried 20~35 minutes in pot, produce isolation coat preparation；Above-mentioned barrier gown layer coating tablet is put in high-efficiency coating pot, preheating temperature
Degree control is at 30~35 DEG C, and 35~45 DEG C of EAT, 25~35 DEG C of temperature of outgoing air, 25~38 DEG C of piece bed tempertaure, coating pan turns
Fast 12-20rpm, 5~10g/min of spray rate, start the continuous hydrophobic coating agent that sprays into and coat separation layer, wait to have whitewashed
Finish, send hot blast to be dried 30~40 minutes in high-efficiency coating pot, produce controlled release coat preparation；Controlled release coat piece is put into high-efficiency coating
In pot, 30~35 DEG C, 35~45 DEG C of EAT, 25~35 DEG C of temperature of outgoing air, 25~40 DEG C of piece bed tempertaure, coating pan are preheated to
Rotating speed 10-25rpm, 8~20g/min of spray rate, start the continuous enteric-coating material that sprays into and coat controlled release layer, wait to have whitewashed
Finish, send hot blast to be dried 30~40 minutes in high-efficiency coating pot, put 40 DEG C of baking oven for drying solidification 12 hours, produce pulse controlled release bag
Clothing preparation.
2. the Orally taken pulsed controlled-release administrating system of a kind of Zolpidemtar Trate according to claim 1, it is characterised in that in power
Profit requires to need to add plasticizer in the coating solution of the barrier gown layer, controlled release clothing layer and enteric coating layer of the pulse controlled release portion described in 1,
The plasticizer is selected from triethyl citrate, phthalic acid diformazan/second/the third/butyl ester, dibutyl sebacate, castor oil, poly- second
One or both of glycol, propane diols, Tween-80, plasticizer consumption are 2~35%.
3. the Orally taken pulsed controlled-release administrating system of a kind of Zolpidemtar Trate according to claim 1, it is characterised in that in power
Profit requires to need to add antiplastering aid in the coating solution of the barrier gown layer, controlled release clothing layer and enteric coating layer of pulse controlled release portion described in 1, disappeared
Infusion, opacifier and colouring agent；Antiplastering aid be selected from talcum powder, magnesium stearate, glycerin monostearate, calcium stearate, stearic acid,
Sodium stearyl fumarate；Defoamer selects dimethicone, and opacifier selects titanium dioxide；Colouring agent is selected from natural or synthetic
Medicinal pigment.
4. the Orally taken pulsed controlled-release administrating system of a kind of Zolpidemtar Trate described in claim 1 is being prepared for treating person in middle and old age
Application in the pharmaceutical preparation of property early awakening disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410230633.1A CN103976972B (en) | 2014-05-26 | 2014-05-26 | Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410230633.1A CN103976972B (en) | 2014-05-26 | 2014-05-26 | Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103976972A CN103976972A (en) | 2014-08-13 |
| CN103976972B true CN103976972B (en) | 2017-09-12 |
Family
ID=51269302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410230633.1A Active CN103976972B (en) | 2014-05-26 | 2014-05-26 | Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103976972B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106137996A (en) * | 2015-03-23 | 2016-11-23 | 江苏天士力帝益药业有限公司 | A kind of (+)-Zopiclone secondary delivery formulations |
| CN106806351A (en) * | 2017-03-30 | 2017-06-09 | 成都绿林科技有限公司 | A kind of preparation with zolpidem as main chemical compositions and preparation method thereof |
| CN111686083B (en) * | 2020-06-10 | 2022-04-22 | 石药集团中奇制药技术（石家庄）有限公司 | Ilaprazole enteric-coated tablet |
| CN115219306B (en) * | 2022-08-15 | 2022-12-09 | 南京派诺思科学仪器有限公司 | Standard substance for disintegration time limit test and preparation and test methods thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005092336A1 (en) * | 2004-03-26 | 2008-02-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Dissolution control preparation and production method thereof |
| CN101288652A (en) * | 2007-09-30 | 2008-10-22 | 西北工业大学 | Water-soluble drug sustained-release tablet and preparation method thereof |
| CN101574328B (en) * | 2009-06-18 | 2010-10-27 | 中国药科大学 | Timing pulsed release micro-pill of zolpidem salt |
| CN103230381B (en) * | 2013-05-14 | 2014-12-17 | 中国药科大学 | Zolpidem tartrate time-selecting pulse sustained-release pellet and preparation method thereof |
-
2014
- 2014-05-26 CN CN201410230633.1A patent/CN103976972B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103976972A (en) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019268052A1 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| CN1489455B (en) | Delayed release pharmaceutical formulations | |
| CN110035757B (en) | Olaparib oral sustained and controlled release pharmaceutical composition and application thereof | |
| CN104220068B (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| CN101987091B (en) | Venlafaxine hydrochloride sustained-release pellet capsules | |
| TWI590835B (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| CN103976972B (en) | Orally taken pulsed controlled-release administrating system of Zolpidemtar Trate and preparation method thereof | |
| CN103417505A (en) | Huperzine A controlled release preparation having biphasic release behavior, and preparation method thereof | |
| CN103054826A (en) | Orally disintegrating tablet of memantine hydrochloride sustained-release pellets and preparation method thereof | |
| CN110062628A (en) | A kind of Rui Kapabu takes orally sustained and controlled release medicament composition and application thereof | |
| WO2019130749A1 (en) | Novel fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
| CN104546666A (en) | Fidaxomicin solid dispersion and preparation method thereof | |
| WO2018108151A1 (en) | Veliparib sustained controlled release pharmaceutical composition and use thereof | |
| CN102764243B (en) | Aspirin pulsed release pellets, its preparation and preparation method thereof | |
| CN109646417B (en) | Trimetazidine sustained release tablet and preparation method thereof | |
| CN101081217A (en) | Slow-release small pill prparation containing huperzine A and method for making same | |
| JP2002212104A (en) | Preparation containing talc/barium sulfate | |
| CN104382882B (en) | A kind of Zaleplon dipulse release capsule of non-TCP friendly flow and preparation method thereof | |
| CN107362161B (en) | Compound captopril nifedipine pulse sustained-release preparation and preparation method thereof | |
| US11759471B2 (en) | Modified release pharmaceutical composition and method for the treatment of mental disorders | |
| CN111888339B (en) | Metformin hydrochloride enteric-coated tablet and preparation method thereof | |
| CN103230379A (en) | Orally disintegrating sustained-release preparation containing tamsulosin hydrochloride and preparation method thereof | |
| CN103181886A (en) | Artemisinin or its derivative sustained release preparation, and preparation method thereof | |
| CN101766608B (en) | Compound pseudoephedrine hydrochloride slow release preparation and preparing method thereof | |
| CN108186696B (en) | Bilobalide double-layer controlled release tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220128 Address after: 221000 No.18, Yangshan Road, Xuzhou Economic and Technological Development Zone, Xuzhou City, Jiangsu Province Patentee after: NHWA PHARMA. Corp. Address before: No. 639 Jiangning longmian Road District of Nanjing City, Jiangsu province 211198 Patentee before: CHINA PHARMACEUTICAL University |
|
| TR01 | Transfer of patent right |